Hugel Inc
KOSDAQ:145020
Hugel Inc
Income from Continuing Operations
Hugel Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Income from Continuing Operations
₩143.1B
|
CAGR 3-Years
34%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Income from Continuing Operations
₩418.9B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
14%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Income from Continuing Operations
-₩50.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
N
|
NatureCell Co Ltd
KOSDAQ:007390
|
Income from Continuing Operations
₩1.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
6%
|
CAGR 10-Years
-4%
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Income from Continuing Operations
₩88.9B
|
CAGR 3-Years
24%
|
CAGR 5-Years
43%
|
CAGR 10-Years
26%
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Income from Continuing Operations
₩60.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
52%
|
|
Hugel Inc
Glance View
In the bustling landscape of the global biopharmaceutical market, Hugel Inc. stands out as a formidable player rooted in the dynamic world of aesthetics and medical treatments. Established in South Korea, Hugel Inc. embarked on its journey with a focus on producing botulinum toxin products, a niche that has rapidly expanded due to a surge in demand for non-surgical cosmetic procedures. The company navigated early challenges with innovative prowess, crafting a strong reputation for high-quality products that cater to a global clientele. The ethos of innovation and safety permeates its operations, enabling Hugel to diversify its portfolio and steadily gain traction in international markets, including significant footprints in Asia, Europe, and Latin America. Through a network of strategic partnerships and a robust distribution channel, Hugel not only pioneered advancements in cosmetic treatments but also cemented its status as a key contributor to the evolving aesthetics industry. The company's revenue model hinges upon the development, production, and distribution of its botulinum toxin and hyaluronic acid-based products. By focusing on research and development, Hugel enhances its capacity to innovate, delivering cutting-edge solutions that meet the rising demands of beauty-conscious consumers. Its business strategy also extends to therapeutics, exploring potential applications of its core products to address various medical conditions. Hugel's financial growth is propelled by the continuous expansion into new geographical territories and the gradual introduction of new, clinically-researched products. As the company continues to navigate the intricate regulatory landscapes of the pharmaceutical industry, it maintains an unwavering commitment to quality, ensuring that each product meets rigorous safety standards while catering to the evolving desires of its diverse customer base worldwide.
See Also
What is Hugel Inc's Income from Continuing Operations?
Income from Continuing Operations
143.1B
KRW
Based on the financial report for Dec 31, 2024, Hugel Inc's Income from Continuing Operations amounts to 143.1B KRW.
What is Hugel Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
23%
Over the last year, the Income from Continuing Operations growth was 47%. The average annual Income from Continuing Operations growth rates for Hugel Inc have been 34% over the past three years , 23% over the past five years .
You don't have any saved screeners yet